What is DNA X, Inc.'s earnings per share (EPS)?

DNA X, Inc. (SONM) reported diluted earnings per share of -$28.58 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

DNA X, Inc. (SONM) Financials

SONM

FY2025 annual

Revenue Not reported for FY2025

Net Income -$20.7M +38.6% YoY

EPS (Diluted) -$28.58 YoY not available

Operating Cash Flow -$23.5M -177.2% YoY

Market Cap $4.7M as of Oct 15, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 19, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 19, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SONM SEC filings page.

This page shows DNA X, Inc. (SONM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SONM FY2025 2026-10-04

The business’s reported losses now consume more cash, while liabilities exceed assets and financing supplies much of its funding.

Between FY2024 and FY2025, the net loss narrowed from $33.6M to $20.7M, yet operating cash flow worsened from -$8.5M to -$23.5M. That earnings-to-cash divergence indicates the improved accounting result did not translate into better cash generation.

The balance sheet shifted from already-thin liquidity in FY2024 to a more constrained FY2025 position: the current ratio fell from 0.7 to 0.6, while liabilities reached $50.6M against assets of $43.9M. This left negative equity of -$8.0M, so financing structure matters more than revenue-based margins.

The operating model improved markedly through FY2023, when gross margin reached 20.6% and operating income was nearly break-even, but FY2024 revenue fell to $58.3M and operating income returned to a $3.1M loss. Meanwhile, FY2025 financing cash flow of $19.5M partly offset operating cash use, showing that external funding has been important to the reported cash position.

Financial Health Signals

Financial health score not available

DNA X, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

DNA X, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

DNA X, Inc. reported a net loss of $20.7M while operations used $23.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

DNA X, Inc. reported an operating loss of $5.4M against $945K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$1.2M

YoY+83.3%

QoQ-119.7%

DNA X, Inc. reported -$1.2M in net income in Q2 2026. This represents an increase of 83.3% from the same quarter a year earlier. Against the prior quarter it is down 119.7%.

EPS (Diluted)

-$0.92

QoQ-118.4%

DNA X, Inc. earned -$0.92 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 118.4%.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$900K

YoY-55.1%

QoQ-24.7%

5Y CAGR-33.5%

DNA X, Inc. held $900K in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

QoQ0.0%

5Y CAGR-55.5%

DNA X, Inc. had 1M shares outstanding in Q2 2026. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

None of these metrics is reported for Q2 2026.

Capital Allocation

None of these metrics is reported for Q2 2026.

SONM Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SONM quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Revenue	N/A	N/A	$58.3M-37.7%	$93.6M+34.1%	$69.8M+28.0%	$54.6M-14.7%	$64.0M-45.0%	$116.3M-14.3%	$135.7M
Cost of Revenue	N/A	N/A	$48.4M-34.9%	$74.3M+27.7%	$58.2M+20.9%	$48.2M-1.3%	$48.8M-40.3%	$81.7M-6.7%	$87.6M
Gross Profit	N/A	N/A	$9.9M-48.7%	$19.3M+66.3%	$11.6M+81.2%	$6.4M-57.8%	$15.2M-55.9%	$34.5M-28.2%	$48.1M
R&D Expenses	N/A	N/A	$14.2M+703.3%	$1.8M-77.8%	$8.0M-54.9%	$17.7M+9.1%	$16.2M-37.8%	$26.1M+12.1%	$23.2M
SG&A Expenses	N/A	$5.4M+74.4%	$3.1M-62.5%	$8.3M-22.5%	$10.7M+3.7%	$10.3M+4.6%	$9.8M-34.8%	$15.1M+109.0%	$7.2M
Operating Income	N/A	-$5.4M-74.4%	-$3.1M-704.3%	$513K+103.6%	-$14.3M+62.4%	-$38.0M-29.9%	-$29.3M-30.7%	-$22.4M-514.9%	$5.4M
EBITDA	N/A	-$1.1M-342.0%	$457K-83.2%	$2.7M+122.8%	-$11.9M+66.8%	-$35.9M-35.2%	-$26.5M-40.7%	-$18.9M-360.3%	$7.2M
Interest Expense	N/A	$945K+3158.6%	$29K+93.3%	$15K-84.5%	$97K	N/A	$759K-50.1%	$1.5M-16.7%	$1.8M
Income Tax	N/A	-$1.1M-607.1%	$226K-39.6%	$374K+103.3%	$184K+10.2%	$167K+132.1%	-$521K-137.5%	$1.4M+84.1%	$754K
Net Income	N/A	-$20.7M+38.6%	-$33.6M-37286.7%	-$90K+99.4%	-$14.1M+63.5%	-$38.6M-29.0%	-$29.9M-15.9%	-$25.8M-2123.0%	$1.3M
EPS (Basic)	N/A	-$28.58+77.7%	-$128.37-641750.0%	-$0.02+95.9%	-$0.49+88.0%	-$4.08	N/A	N/A	N/A
EPS (Diluted)	-$10.18	-$28.58	-$128.37	-$0.02	-$0.49	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	722,689	262,118	4M	29M	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	N/A	N/A	$16.2M+7.9%	$11.2M-2.8%	$16.7M-0.3%	$15.0M+11.6%	$15.0M-45.5%
Cost of Revenue	N/A	N/A	N/A	$11.9M+30.3%	$7.8M+15.2%	$8.4M-39.7%	$18.6M+123.7%	$9.1M-58.6%
Gross Profit	N/A	N/A	N/A	$1.8M-57.1%	$845K-71.5%	$8.4M+187.9%	-$183K-103.6%	$4.2M-24.5%
R&D Expenses	N/A	N/A	N/A	$181K-74.7%	$909K+63.2%	$1.6M+258.1%	$12.5M	$715K-3.5%
SG&A Expenses	$1.3M-13.1%	$3.6M+315.9%	N/A	$3.2M+11.1%	$1.5M-39.9%	$870K-67.1%	-$4.8M-301.7%	$2.8M+39.5%
Operating Income	-$1.3M+13.1%	-$3.6M-315.9%	N/A	-$4.0M-67.5%	-$1.5M+77.3%	-$870K+67.6%	$8.4M+772.1%	-$2.4M-445.3%
EBITDA	N/A	N/A	N/A	-$3.0M-107.7%	-$674K+88.0%	$185K+110.2%	$9.3M+3226.8%	-$1.5M-293.1%
Interest Expense	$140K-13.0%	$131K+84.5%	N/A	$339K	$161K+847.1%	$71K	N/A	N/A
Income Tax	-$243K-276.1%	$2.5M+1822.7%	N/A	$90K-23.1%	$138K+273.0%	$132K+5.6%	-$53K-157.0%	$117K+21.9%
Net Income	-$1.2M+83.3%	$6.3M+1284.3%	N/A	-$4.8M-89.2%	-$7.5M-13.0%	$458K+115.8%	-$21.6M-1497.5%	-$2.5M-576.7%
EPS (Basic)	-$0.92+93.5%	$5.01+255.3%	-$9.44-107.5%	-$4.83+48.2%	-$14.15-903.5%	$1.41+316.9%	-$4.55-15066.7%	-$9.32-7866.7%
EPS (Diluted)	-$0.92	$5.01	-$9.44	-$4.83	-$14.15	$1.41	-$4.55	-$9.32
Diluted Shares (Avg)	1M	1M	N/A	984,927	528,367	324,431	N/A	269,388

SONM Balance Sheet

SONM quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Total Assets	$43.9M+10.5%	$39.7M-29.1%	$56.0M+4.4%	$53.7M+30.7%	$41.1M-18.3%	$50.3M-9.3%	$55.5M-17.6%	$67.3M
Current Assets	$28.9M-10.1%	$32.2M-26.5%	$43.8M+0.4%	$43.6M+22.3%	$35.7M-21.7%	$45.6M-3.7%	$47.3M-25.9%	$63.9M
Cash & Equivalents	$1.3M-75.6%	$5.3M-43.1%	$9.4M-28.9%	$13.2M+17.6%	$11.2M-49.3%	$22.1M+96.0%	$11.3M-13.4%	$13.0M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	$10.6M+63.0%	$6.5M+66.7%	$3.9M-29.5%	$5.5M-51.1%	$11.3M-41.9%	$19.5M-10.5%	$21.8M
Accounts Receivable	N/A	$4.3M-82.9%	$25.3M+12.8%	$22.4M+107.7%	$10.8M+160.2%	$4.2M-58.8%	$10.1M-46.6%	$18.9M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$50.6M+11.4%	$45.4M+34.9%	$33.7M+0.1%	$33.6M+49.8%	$22.5M+2.5%	$21.9M-26.8%	$29.9M-51.9%	$62.2M
Current Liabilities	$50.6M+15.7%	$43.7M+36.1%	$32.1M+0.3%	$32.1M+52.8%	$21.0M+2.5%	$20.5M-25.8%	$27.6M-42.7%	$48.2M
Non-Current Liabilities	$0-100.0%	$1.7M+11.2%	$1.5M-3.2%	$1.6M+7.1%	$1.5M+3.3%	$1.4M-38.5%	$2.3M-83.4%	$14.0M
Long-Term Debt	$5.1M	N/A	N/A	N/A	$66K-64.3%	$185K-48.9%	$362K-97.3%	$13.2M
Total Equity	-$8.0M-39.6%	-$5.7M-125.5%	$22.4M+11.6%	$20.0M+7.6%	$18.6M-34.4%	$28.4M+11.3%	$25.5M+397.7%	$5.1M
Retained Earnings	-$304.3M-7.3%	-$283.6M-13.5%	-$250.0M0.0%	-$249.9M-6.4%	-$234.8M-19.7%	-$196.2M-18.0%	-$166.2M-15.8%	-$143.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$4.5M-87.5%	$4.8M-86.5%	$43.9M+10.5%	$40.2M-18.2%	$36.1M-21.3%	$36.0M-15.2%	$39.7M-29.1%	$49.1M-16.1%
Current Assets	$2.9M-89.2%	$3.3M-87.7%	$28.9M-10.1%	$30.3M-10.5%	$27.1M-16.8%	$26.9M-8.8%	$32.2M-26.5%	$33.9M-28.8%
Cash & Equivalents	$900K-55.1%	$1.2M-43.5%	$1.3M-75.6%	$2.1M-76.4%	$2.0M-79.1%	$2.1M-77.1%	$5.3M-43.1%	$9.1M-7.5%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	N/A	$11.0M-11.2%	$9.9M+40.9%	$8.6M+78.7%	$10.6M+63.0%	$12.4M+193.3%
Accounts Receivable	N/A	$57K-98.8%	N/A	$3.5M-33.2%	$2.9M-64.7%	$4.8M-35.5%	$4.3M-82.9%	$5.2M-82.7%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$5.7M-84.6%	$4.9M-86.7%	$50.6M+11.4%	$40.9M+21.1%	$37.4M+31.7%	$37.0M+64.3%	$45.4M+34.9%	$33.8M-4.8%
Current Liabilities	$5.1M-85.6%	$4.3M-87.5%	$50.6M+15.7%	$38.9M+20.7%	$35.7M+32.6%	$34.7M+65.3%	$43.7M+36.1%	$32.2M-5.4%
Non-Current Liabilities	$600K-65.7%	$600K-74.6%	$0-100.0%	$2.1M+27.9%	$1.8M+16.1%	$2.4M+50.2%	$1.7M+11.2%	$1.6M+10.4%
Long-Term Debt	N/A	$1.1M+89.4%	$5.1M	$250K	$2.9M	$566K	N/A	N/A
Total Equity	-$1.2M+7.6%	-$983K+8.9%	-$8.0M-39.6%	-$701K-104.6%	-$1.3M-107.6%	-$1.1M-105.4%	-$5.7M-125.5%	$15.3M-33.6%
Retained Earnings	-$298.9M-2.8%	-$297.6M-5.1%	-$304.3M-7.3%	-$295.4M-12.7%	-$290.6M-12.0%	-$283.1M-12.0%	-$283.6M-13.5%	-$262.0M-5.4%

Not reported in any period shown, so not listed: Goodwill.

SONM Cash Flow Statement

SONM quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Operating Cash Flow	-$14.5M	-$23.5M-177.2%	-$8.5M-109.4%	-$4.1M+67.2%	-$12.4M+67.9%	-$38.5M-264.4%	-$10.6M+68.5%	-$33.5M-968.2%	$3.9M
Depreciation & Amortization	N/A	$4.3M+20.9%	$3.6M+61.2%	$2.2M-7.1%	$2.4M+11.6%	$2.1M-22.0%	$2.7M-22.6%	$3.5M+90.5%	$1.9M
Stock-Based Compensation	N/A	$1.5M+1.0%	$1.5M+1.9%	$1.5M-3.5%	$1.6M+42.9%	$1.1M-0.2%	$1.1M-82.8%	$6.3M+2403.2%	$252K
Capital Expenditures	N/A	N/A	$214K+494.4%	$36K+350.0%	$8K-82.6%	$46K+318.2%	$11K-98.9%	$992K+26.0%	$787K
Free Cash Flow	N/A	N/A	-$8.7M-112.8%	-$4.1M+66.9%	-$12.4M+67.9%	-$38.5M-264.4%	-$10.6M+69.4%	-$34.5M-1222.8%	$3.1M
Investing Cash Flow	N/A	N/A	-$214K-494.4%	-$36K-350.0%	-$8K+82.6%	-$46K-318.2%	-$11K+99.2%	-$1.4M+46.7%	-$2.5M
Financing Cash Flow	N/A	$19.5M+319.4%	$4.6M+1608.1%	$272K-98.1%	$14.3M-48.0%	$27.6M+29.0%	$21.4M-35.4%	$33.1M+226.3%	$10.2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$2.0M+59.0%	-$3.5M+63.9%	-$2.0M+55.6%	-$7.0M-1586.8%	-$4.9M-43.9%	-$9.6M-5617.9%	-$4.5M-1184.6%	-$417K-37.2%
Depreciation & Amortization	N/A	N/A	$1.5M+63.7%	$952K+3.7%	$797K-5.7%	$1.1M+19.9%	$914K-4.4%	$918K+1270.1%
Stock-Based Compensation	$98K-89.4%	$304K+4.8%	N/A	$166K-55.5%	$926K+96.2%	$290K-10.5%	N/A	$373K+0.5%
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$8K-33.3%	$137K+13600.0%
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$4.5M-1144.4%	-$554K-81.6%
Investing Cash Flow	-$94K	$3.4M	N/A	N/A	N/A	N/A	-$8K+33.3%	-$137K-13600.0%
Financing Cash Flow	N/A	N/A	$1.2M+46.3%	$7.2M+51078.6%	$4.8M+26.3%	$6.4M+11934.0%	$800K+2262.2%	$14K-96.3%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

SONM Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SONM quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Gross Margin	N/A	17.0%-3.6pp	20.6%+4.0pp	16.7%+4.9pp	11.8%-12.0pp	23.8%-5.9pp	29.7%-5.8pp	35.4%
Operating Margin	N/A	-5.3%-5.9pp	0.5%+21.0pp	-20.5%+49.2pp	-69.6%-23.9pp	-45.7%-26.5pp	-19.3%-23.2pp	4.0%
Net Margin	N/A	-57.7%-57.6pp	-0.1%+20.1pp	-20.2%+50.6pp	-70.8%-24.0pp	-46.8%-24.6pp	-22.2%-23.2pp	0.9%
Return on Equity	N/A	N/A	-0.4%+69.9pp	-70.3%+137.1pp	-207.3%-102.0pp	-105.4%-4.2pp	-101.2%-126.1pp	24.9%
Return on Assets	-47.1%+37.6pp	-84.7%-84.5pp	-0.2%+26.1pp	-26.2%+67.8pp	-94.0%-34.5pp	-59.5%-12.9pp	-46.6%-48.5pp	1.9%
Current Ratio	0.57-0.2x	0.74-0.6x	1.360.0x	1.36-0.3x	1.70-0.5x	2.23+0.5x	1.71+0.4x	1.33
Debt-to-Equity	N/A	N/A	1.51-0.2x	1.68+1.7x	0.000.0x	0.010.0x	0.01-2.6x	2.58
Asset Turnover	N/A	1.47-0.2x	1.67+0.4x	1.300.0x	1.33+0.1x	1.27-0.8x	2.10+0.1x	2.01
FCF Margin	N/A	-14.9%-10.5pp	-4.4%+13.3pp	-17.7%+52.9pp	-70.6%-54.1pp	-16.5%+13.2pp	-29.7%-32.0pp	2.3%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	N/A	N/A	N/A	11.2%-17.0pp	7.5%-18.2pp	50.0%+32.7pp	-1.2%-39.3pp	28.2%+7.8pp
Operating Margin	N/A	N/A	N/A	-24.6%-8.7pp	-13.2%+43.0pp	-5.2%+10.8pp	56.3%+65.6pp	-15.8%-18.3pp
Net Margin	N/A	N/A	N/A	-29.3%-12.6pp	-66.8%-9.4pp	2.7%+20.1pp	-144.3%	-16.7%-18.6pp
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-16.4%-18.6pp
Return on Assets	-27.6%-6.9pp	131.1%+129.8pp	N/A	-11.8%-6.7pp	-20.7%-6.3pp	1.3%+8.1pp	-54.4%-52.0pp	-5.1%-6.0pp
Current Ratio	0.57-0.2x	0.760.0x	0.57-0.2x	0.78-0.3x	0.76-0.5x	0.78-0.6x	0.74-0.6x	1.05-0.3x
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	2.20+0.7x
Asset Turnover	N/A	N/A	N/A	0.40+0.1x	0.31+0.1x	0.47+0.1x	0.38+0.1x	0.31-0.2x
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-30.1%-27.4pp	-3.7%-2.6pp

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Note: Shareholder equity is negative (-$8.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.57), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
DNA X, Inc. SONM	FY2025	N/A	-$20.7M	N/A	$4.7M	—
Silynxcom Ltd. SYNX	FY2025	$5.8M	-$3.1M	-52.8%	$5.5M	23/100
Moving iMage Technologies, Inc. MITQ	FY2026	$17.3M	-$297K	-1.7%	$5.4M	37/100
ClearOne, Inc. CLRO	FY2025	$0	N/A	N/A	$10.1M	—
UTStarcom Holdings Corp UTSI	FY2025	$9.0M	-$8.0M	-88.5%	$22.5M	51/100
Cambium Networks Corporation CMBM	FY2025	$159.6M	-$38.5M	-24.1%	$11.3M	38/100

Where DNA X, Inc. Ranks

Frequently Asked Questions

Is DNA X, Inc. profitable?

No, DNA X, Inc. (SONM) reported a net income of -$20.7M in fiscal year 2025.

What is DNA X, Inc.'s EBITDA?

DNA X, Inc. (SONM) had EBITDA of -$1.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does DNA X, Inc. have?

As of fiscal year 2025, DNA X, Inc. (SONM) had $1.3M in cash and equivalents against $5.1M in long-term debt.

What is DNA X, Inc.'s operating cash flow?

DNA X, Inc. (SONM) recorded an outflow of $23.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are DNA X, Inc.'s total assets?

DNA X, Inc. (SONM) had $43.9M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does DNA X, Inc. have outstanding?

DNA X, Inc. (SONM) had 1M shares outstanding as of fiscal year 2025.

What is DNA X, Inc.'s current ratio?

DNA X, Inc. (SONM) had a current ratio of 0.57 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is DNA X, Inc.'s return on assets (ROA)?

DNA X, Inc. (SONM) had a return on assets of -47.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is DNA X, Inc.'s P/E ratio?

DNA X, Inc. (SONM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $4.7M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is DNA X, Inc.'s price-to-sales ratio?

DNA X, Inc. (SONM) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $4.7M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Why is DNA X, Inc.'s debt-to-equity ratio negative or not reported?

DNA X, Inc. (SONM) has negative shareholder equity of -$8.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is DNA X, Inc.'s Piotroski F-Score?

DNA X, Inc. (SONM) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are DNA X, Inc.'s earnings high quality?

DNA X, Inc. (SONM) reported a net loss of $20.7M while operations used $23.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can DNA X, Inc. cover its interest payments?

DNA X, Inc. (SONM) reported an operating loss of $5.4M against $945K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.